Previous 10 | Next 10 |
WALTHAM, Mass., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced the completion of targeted enrollment of 30 patients ah...
200 mg BID dose demonstrates receptor saturation and statistically significant increases in key circulating T lymphocyte populations Lymphocyte changes consistent with approved α4β7 inhibitor WALTHAM, Mass., Oct. 10, 2022 (GLOBE NEWSWIRE) -- Morphic The...
Recognized for pioneering work in field of integrin receptor biology, leading to new treatments for multiple autoimmune disorders Founder, Director, and Scientific Advisory Board member of Morphic Therapeutic WALTHAM, Mass., Sept. 28, 2022 (GLOBE NEWSWIRE) -- Morphic The...
Paper describes key insight into integrin conformation, overcoming critical drug development challenge Company lauds Tim Springer, PhD, scientific founder of Morphic and Fu-Yang “Albert” Lin, PhD, first company employee WALTHAM, Mass., Sept. 21, 2022 (GLOBE N...
WALTHAM, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that members of its management team will participate i...
Morphic press release ( NASDAQ: MORF ): Q2 GAAP EPS of -$0.68 beats by $0.17 . Revenue of $60.2M (+1463.6% Y/Y). As of June 30, 2022, Morphic had cash, cash equivalents and marketable securities of $397.6 million, compared to $380.7 million as of March 31, 2022. ...
Continued enrollment of EMERALD-1 phase 2a trial of MORF-057 in patients with ulcerative colitis Announced key appointments and advancements in leadership team Ended second quarter 2022 with $397.6 million in cash and equivalents Cash runway extended into second ...
For further details see: Morphic coverage initiated with Outperform by SVB Securities
Clinical-stage biotech Morphic Holding (NASDAQ:MORF) announced that AbbVie (ABBV) has decided to terminate the collaboration and option agreement the pharma giant inked with its subsidiary Morphic Therapeutic in 2018 for integrin therapeutics. Integrins are a class of receptors that use both ...
Gainers: Novavax (NVAX) +259%. Precision BioSciences (DTIL) +114%. Amazon.com (AMZN) +39%. Adobe (ADBE) +32%. Paratek Pharmaceuticals (PRTK) +15%. Losers:Euronet Worldwide (EEFT) -5%. Seres Therapeutics (MCRB) -5%. Sanderson Farms (SAFM) -5%. Morphic Holding (MORF) -4%. Redbox Entertainm...
News, Short Squeeze, Breakout and More Instantly...
2024-07-23 06:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-09 08:15:05 ET RBC Capital analyst issues SECTOR PERFORM recommendation for MORF on July 9, 2024 06:29AM ET. The previous analyst recommendation was Outperform. MORF was trading at $55.74 at issue of the analyst recommendation. The overall analyst consensus : BUY...
2024-07-08 20:00:07 ET Edward Nash from Canaccord Genuity issued a price target of $57.00 for MORF on 2024-07-08 18:49:00. The adjusted price target was set to $57.00. At the time of the announcement, MORF was trading at $55.74. The overall price target consensus is at $...